Global Blood Therapeutics Inc. (GBT) Well Positioned Following Oxbryta KOL Survey - Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $120.00 price target on Global Blood Therapeutics (NASDAQ: GBT) citing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
